Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is modest, for now. We plan to catch up on our reading, promenade with the official mascot, and putter around the castle. And what about you? This remains a fine time to enjoy the great outdoors. You could boost the economy by getting a jump on holiday shopping. Or you could reach out to someone who may be feeling isolated right now. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …

After a rocky start, Food and Drug Commissioner Stephen Hahn has won over critics, The Wall Street Journal tell us. The agency’s success in earning the backing of the Trump administration for a rigorous approval process for a Covid-19 vaccine eased fears it was putting politics before science. “He stood up to Trump and he’s doing the right thing with vaccines,” says Eric Topol, director of the Scripps Research Translational Institute.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.